27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of COVID-19 vaccine company Moderna, Inc. (NASDAQ:MRNA), which ended Thursday's session with a market cap of $104.3 billion by virtue of a 5.28% rally, are seeing follow-through buying interest Friday.
Standard & Poor's announced late Thursday Moderna will join the S&P 500 Index, effective before the market opens Wednesday, July 21.
Moderna will replace Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), which is to be acquired by U.K. pharma giant AstraZeneca plc (NASDAQ:AZN) in a deal expected to be completed soon pending final closing conditions.
Index inclusion is usually positive for stocks, as funds holding portfolios mirroring the index will buy into the stocks to maintain the respective weightings of the component stocks. The stock will also benefit from increased volume and liquidity due to purchases by index funds and ETFs.
Moderna is one of the early entrants into the COVID-19 vaccine market, having secured authorization for emergency use of its vaccine in countries including the U.S., EU, Canada U.K., Israel and India.
Moderna closed with a market cap of over $100 billion for the first time on Thursday.
In premarket trading Friday, Moderna shares were advancing 7.67% to $ 279.60.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!